The Largest Personal Injury Firm in Texas. Serving Clients Nationwide.
Corpus Christi 361-985-0600 San Antonio 210-656-1000 Nationwide Toll Free 888-314-9945
Contact us 24/7

Simtuzumab Drug Fails Mid-Study

View all
Jasjit Mundh3 years ago

Gilead Sciences Inc. has stated that its experimental drug used for improving the lifespan of patients with pancreatic cancer has failed a mid-stage clinical trial.

About the Mid-Study Failure

According to Medscape, the experimental drug, simtuzumab, did not significantly improve how long patients diagnosed with pancreatic cancer live without their disease worsening. The study failed in its main goal of improving progression-free-survival (PFS).  More details of the study can be found below.

Simtuzumab is also being tested for use in colorectal cancer, myelofibrosis, idiopathic pulmonary fibrosis, and liver fibrosis.

Description of the Simtuzumab Study

  • The study evaluated simtuzumab (in combination with chemotherapy) against a placebo (plus chemotherapy) in previously untreated patients with advanced pancreatic cancer.
  • There was no statistically significant difference in PFS between patients on simtuzumab and those on the placebo.


Contact Us for a FREE Case Review

888-314-9945 •